Previous close | 12.50 |
Open | 12.80 |
Bid | 12.55 |
Ask | 13.60 |
Strike | 660.00 |
Expiry date | 2024-10-18 |
Day's range | 12.35 - 12.80 |
Contract range | N/A |
Volume | |
Open interest | 130 |
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.